Abao, Chrismalice C.
HRN: 00-74-16 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/02/2024
CO-AMOXICLAV 625MG (TAB)
04/02/2024
04/09/2024
PO
625mg
BID
S/p Nsvd With Rmle
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes